Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $698,628.40 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 4,376 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $159.65, for a total value of $698,628.40. Following the completion of the sale, the insider directly owned 43,405 shares in the company, valued at $6,929,608.25. This represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $152.80 on Friday. The stock has a 50 day moving average price of $145.35 and a 200 day moving average price of $137.14. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $160.18. The stock has a market capitalization of $15.24 billion, a price-to-earnings ratio of 36.56, a PEG ratio of 1.02 and a beta of 0.27.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $794.90 million for the quarter, compared to analysts’ expectations of $746.61 million. During the same quarter in the previous year, the company posted $1.81 EPS. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. On average, analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on NBIX shares. Citigroup boosted their price target on shares of Neurocrine Biosciences from $175.00 to $203.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. UBS Group upped their price target on Neurocrine Biosciences from $188.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Canaccord Genuity Group lifted their price objective on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. Finally, Mizuho upped their target price on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $173.33.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. boosted its stake in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after acquiring an additional 100 shares during the last quarter. Eastern Bank purchased a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $27,000. WPG Advisers LLC purchased a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $32,000. Finally, Quent Capital LLC acquired a new stake in Neurocrine Biosciences in the 3rd quarter valued at approximately $32,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.